Education
About Us
Working with TipRanks
Follow Us
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
$38.11
-$0.05(-0.51%)
At close: 4:00 PM EST
$38.11
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$5.83 - $41.00
Previous CloseN/A
Volume96.53K
Average Volume (3M)479.31K
Market Cap
$2.11B
Enterprise Value$645.85M
Total Cash (Recent Filing)$290.88M
Total Debt (Recent Filing)$798.00K
Price to Earnings (P/E)―
Beta0.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding53,679,165
10 Day Avg. Volume272,994
30 Day Avg. Volume479,314
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)68.44
P/FCF Ratio-2.86
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue43.06
Enterprise Value/Gross Profit-19.56
Enterprise Value/Ebitda-3.30
Forecast
1Y Price Target
$45.40Price Target Upside19.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.1
Revenue Forecast (FY)$40.00M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsZenas BioPharma announced strong, positive Ph2 MoonStone results for obexelimab in relapsing multiple sclerosis, demonstrating a 95% statistically significant reduction in new Gd-enhancing T1 lesions versus placebo.
Financial StabilityZBIO has pro-forma cash of ~$403.6M, following a recent private placement financing, with a runway into 4Q26.
Strategic LicensingThe announced license agreement between Zenas BioPharma and InnoCare Pharma allows Zenas to expand its pipeline by including Orelabrutinib, which addresses unmet needs in multiple sclerosis treatment.
Bears Say
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $5.83 and its highest was $41.00 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $2.11B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Aug 12, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$1.038 by -$0.212.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 53,679,165 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.25 in its last earnings report, missing expectations of -$1.038. Following the earnings report the stock price went up 1.705%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
Zenas BioPharma, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.40 (19.13% Upside)
$45.40 (19.13% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $18.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
287.29%
12-Months-Change
Fundamentals
Return on Equity
-68.33%
Trailing 12-Months
Asset Growth
-20.18%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. (ZBIO) is a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases and unmet medical needs. The company specializes in the discovery, development, and commercialization of biologic products that target specific disease pathways. ZBIO's core product offerings include novel therapeutics that aim to improve patient outcomes in areas such as immunology and oncology, leveraging advanced biotechnological techniques to create effective treatment options.
ZBIO Stock 12 Month Forecast
Average Price Target
$45.40
▲(19.13% Upside)